SCHEMBL13629329

SCHEMBL13629329

CCc1ccc(NS(=O)(=O)c2cc(Cl)ccc2Cl)cc1C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.65
LMNA P02545 2/20 0.65
CDK1 P06493 1/20 0.63
CCNB1 P14635 1/20 0.63
CCNA2 P20248 1/20 0.63
CDK2 P24941 1/20 0.63
CDK7 P50613 1/20 0.63
CCNH P51946 1/20 0.63
CCNA1 P78396 1/20 0.63
MAPT P10636 3/20 0.58
HTT P42858 2/20 0.58
TDP1 Q9NUW8 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
MAPK1 P28482 1/20 0.54
HPGD P15428 2/20 0.53
HSD17B10 Q99714 1/20 0.53
MCL1 Q07820 4/20 0.52
HSP90AA1 P07900 1/20 0.52
HSP90AB1 P08238 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13629296 0.85 ALDH1A1 (0.57) ALDH1A1LMNACDK1CCNB1CCNA2
SCHEMBL13629320 0.85 SLC22A12 (0.54) ALDH1A1LMNAMAPT
SCHEMBL13629465 0.84 LMNA (0.54) ALDH1A1LMNACDK1CCNB1CCNA2
SCHEMBL13629423 0.82 CES1 (0.60) ALDH1A1MAPTTDP1
SCHEMBL13615072 0.81 CDK1 (0.63) ALDH1A1LMNACDK1CCNB1CCNA2
SCHEMBL13629401 0.80 ALDH1A1 (0.65) ALDH1A1LMNACDK1CCNB1CCNA2
SCHEMBL25453798 0.80 CDK1 (0.68) ALDH1A1LMNACDK1CCNB1CCNA2
SCHEMBL30161399 0.80 CDK1 (0.68) ALDH1A1LMNACDK1CCNB1CCNA2
SCHEMBL13629339 0.79 BRD4 (0.51) ALDH1A1LMNACDK1CCNB1CCNA2
SCHEMBL13629553 0.79 PKM (0.56) ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK ALDH1A1 2057/4885LMNA 2891/4885CDK1 339/4885
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK ALDH1A1 2121/4885LMNA 2608/4885CDK1 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.